ClinicalTrials.gg
RecruitingNCT07578363Updated Nov 12, 2026

An Investigation of FID 123472 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness in Adults

A Phase 3 interventional study of Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free and Vehicle in Ocular Hyperemia, sponsored by Alcon Research. Recruiting at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Alcon Research (part of Alcon) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Nov 12, 2026Now RecruitingPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
178
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Hyperemia with a site in United States — 9 open to participants now, 9 under way, 2 of them phase 3. Hyperemia · United States.

Planned enrollment
5th of 19
178 · median 68
Started
2026
with 2 others
Phase 3
6 of 23
2 open now
Registered
22nd of 23
by date
Lead sponsor
2 of 23
Alcon Research

Among the 23 studies in Hyperemia with a site in United States, this one is the 5th largest by planned enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2026, is one of 6 in phase 3, and was the 22nd registered.

Hyperemia

98 studies on the registry are indexed under Hyperemia; 44 are open to participants now.

Browse Hyperemia studies →

Open to participants now

9 of the 23 studies in Hyperemia with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 28 Hyperemia studies recruiting now, 17 (61%) set no upper age limit and 7 (25%) stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Hyperemia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of an investigational ophthalmic solution in adults with ocular redness caused by minor eye irritations.

Read the detailed description

Eligible subjects will be expected to attend a total of 6 in-office study visits over a period of approximately 10 weeks. Subjects will receive a single dose of study treatment in each eye (either Apraclonidine 0.125% UDPF or Vehicle) on Day 1, after which subjects will be instructed to self-administer one drop in each eye twice daily at home for a total of approximately 8 weeks (Days 2-55), with the last dose administered on Day 56 in office. Subjects will then return for the final study visit on Day 63, following a 1-week treatment discontinuation. Eye redness will be assessed before and after instillation at prespecified timepoints.

03

Conditions studied

  • Ocular Hyperemia

Browse trials for

Keywords

  • Ocular Redness
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Capable of giving signed and comply with the requirements listed in the Informed Consent Form.
  • Willing and able to follow all instructions and attend all study visits.
  • History of redness relief eyedrop use within the last 6 months, or an interest in using over-the-counter redness relief drops, or would benefit from the use of redness relief drops in the investigator's opinion.
  • Baseline ocular redness score of 0.5 unit or higher in at least one eye at Visit 1 and greater than 1 unit on a 5-point scale in both eyes prior to randomization at Visit 2.
  • Other protocol-defined inclusion criteria may apply.

Key Exclusion Criteria:

  • Known or sensitivity to the use of any of the study treatment(s) or their components, or any other medication required by the protocol.
  • Ocular surgical interventions within 6 months prior to Visit 1 or during the study.
  • Any ocular condition that, in the opinion of the investigator, may compromise the subject's safety or study parameters.
  • Use of prohibited medications, devices, or treatments as specified in the protocol.
  • Out of range vital signs (blood pressure and/or pulse rate) as defined in the study protocol.
  • Abnormal intraocular pressure.
  • Other protocol-defined exclusion criteria may apply.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
178 participants (estimated)

Study arms

  • Experimental
    Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free

    One drop in each eye on Day 1, followed by one drop in each eye twice daily (approximately 12 hours apart, but not less than 11.5 hours apart) beginning the day following Day 1 up until the day prior to Day 56. On the day of Day 56, subjects will receive the last dose in-office.

    Drug: Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free

  • Placebo comparator
    Vehicle

    One drop in each eye on Day 1, followed by one drop in each eye twice daily (approximately 12 hours apart, but not less than 11.5 hours apart) beginning the day following Day 1 up until the day prior to Day 56. On the day of Day 56, subjects will receive the last dose in-office.

    Drug: Vehicle

Interventions

  • DrugApraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free

    Investigational ophthalmic solution applied topically to the eye in a unit dose preservative free formulation

    Also known as: FID 123472, Apraclonidine 0.125% UDPF

  • DrugVehicle

    Inactive ingredients of FID 123472 applied topically to the eye as an ophthalmic solution in a unit dose preservative free formulation

06

What researchers measure

Primary outcomes

  1. Change from baseline in investigator-assessed ocular redness at 15 minutes post-instillation on Day 1

    Ocular redness will be assessed by the investigator and recorded per the Ora Calibra® Ocular Hyperemia Scale, which ranges from 0 to 4 in half-point increments (0.0 = none; 1.0 = mild redness; 2.0 = moderate redness; 3.0 = severe redness; and 4.0 = extremely severe redness). Change from baseline, calculated as post-instillation minus baseline score, can range between -4 and +2.5. Positive values indicate increased ocular redness (worsening), zero indicates no change, and negative values indicate improvement (decrease in severity). This is a co-primary endpoint.

    Time frame: Baseline (Day 1 pretreatment); 15 minutes post-instillation (Day 1)

  2. Change from baseline in investigator-assessed ocular redness at 600 minutes post-instillation on Day 1

    Ocular redness will be assessed by the investigator and recorded per the Ora Calibra® Ocular Hyperemia Scale, which ranges from 0 to 4 in half-point increments (0.0 = none; 1.0 = mild redness; 2.0 = moderate redness; 3.0 = severe redness; and 4.0 = extremely severe redness). Change from baseline, calculated as post-instillation minus baseline score, can range between -4 and +2.5. Positive values indicate increased ocular redness (worsening), zero indicates no change, and negative values indicate improvement (decrease in severity). This is a co-primary endpoint.

    Time frame: Baseline (Day 1 pretreatment); 600 minutes post-instillation (Day 1)

Secondary outcomes

  1. Change from baseline in investigator-assessed ocular redness at 1 minute post-instillation on Day 1

    Ocular redness will be assessed by the investigator and recorded per the Ora Calibra® Ocular Hyperemia Scale, which ranges from 0 to 4 in half-point increments (0.0 = none; 1.0 = mild redness; 2.0 = moderate redness; 3.0 = severe redness; and 4.0 = extremely severe redness). Change from baseline, calculated as post-instillation minus baseline score, can range between -4 and +2.5. Positive values indicate increased ocular redness (worsening), zero indicates no change, and negative values indicate improvement (decrease in severity).

    Time frame: Baseline (Day 1 pretreatment); 1 minute post-instillation (Day 1)

  2. Change from baseline in investigator-assessed ocular redness at 720 minutes post-instillation on Day 1

    Ocular redness will be assessed by the investigator and recorded per the Ora Calibra® Ocular Hyperemia Scale, which ranges from 0 to 4 in half-point increments (0.0 = none; 1.0 = mild redness; 2.0 = moderate redness; 3.0 = severe redness; and 4.0 = extremely severe redness). Change from baseline, calculated as post-instillation minus baseline score, can range between -4 and +2.5. Positive values indicate increased ocular redness (worsening), zero indicates no change, and negative values indicate improvement (decrease in severity).

    Time frame: Baseline (Day 1 pretreatment); 720 minutes post-instillation (Day 1)

  3. Change from baseline in investigator-assessed ocular redness at 30 seconds post-instillation on Day 1

    Ocular redness will be assessed by the investigator and recorded per the Ora Calibra® Ocular Hyperemia Scale, which ranges from 0 to 4 in half-point increments (0.0 = none; 1.0 = mild redness; 2.0 = moderate redness; 3.0 = severe redness; and 4.0 = extremely severe redness). Change from baseline, calculated as post-instillation minus baseline score, can range between -4 and +2.5. Positive values indicate increased ocular redness (worsening), zero indicates no change, and negative values indicate improvement (decrease in severity).

    Time frame: Baseline (Day 1 pretreatment); 30 seconds post-instillation (Day 1)

  4. Number of subjects who achieve prespecified improvements from baseline in investigator-assessed ocular redness score in both eyes at 30 seconds post-instillation on Day 1

    Ocular redness will be assessed by the investigator and recorded per the Ora Calibra® Ocular Hyperemia Scale, which ranges from 0 to 4 in half-point increments (0.0 = none; 1.0 = mild redness; 2.0 = moderate redness; 3.0 = severe redness; and 4.0 = extremely severe redness). The 30-second score will be compared to the baseline score. The number of subjects with improvements as prespecified in the protocol will be reported.

    Time frame: Baseline (Day 1 pretreatment); 30 seconds post-instillation (Day 1)

07

Study locations

3 of 5 sites recruiting
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2026 (actual). Primary completion is estimated for Nov 2026, 2 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Jan 2027 → Nov 2026 and completion Mar 2027 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2026
First posted
May 11, 2026
StartActual
Sep 27, 2026
Primary completionEst.
Nov 2026was Jan 2027
CompletionEst.
Jan 2027was Mar 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 16, 2026
Sites
5 sites added, 1 site removed
Show 5 added (5 United States)
  • Wyse Eyecare · Northbrook, United States
  • Oculus Research, Inc. · Garner, United States
  • CORE, Inc. · Shelby, United States
  • Total Eye Care PA · Memphis, United States
  • Piedmont Eye Center · Lynchburg, United States
Show 1 removed
  • Contact Alcon Call Center for Trial Locations · Fort Worth, United States
Oct 16, 2026
Primary completion
Jan 2027→Nov 2026
Nov 12, 2026
Study completion
Mar 2027→Jan 2027
Nov 12, 2026
Show all 2 updates
  1. Nov 12, 2026
    Primary completion Jan 2027→Nov 2026
    Study completion Mar 2027→Jan 2027
    + 1 other change: verification date
  2. Oct 16, 2026
    Not yet recruiting→Recruiting
    5 sites added, 1 site removed
    Show 5 added (5 United States)
    • Wyse Eyecare · Northbrook, United States
    • Oculus Research, Inc. · Garner, United States
    • CORE, Inc. · Shelby, United States
    • Total Eye Care PA · Memphis, United States
    • Piedmont Eye Center · Lynchburg, United States
    Show 1 removed
    • Contact Alcon Call Center for Trial Locations · Fort Worth, United States
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07578363
Lead sponsor
Alcon Research
Responsible party
Sponsor
First posted
May 11, 2026
Start date
Sep 27, 2026
Primary completion
Nov 2026 (estimated)
Completion
Jan 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Alcon Call Center
Contact
alcon.medinfo@alcon.com
1-888-451-3937
Clinical Trial Lead, Pharma
study director · Alcon Research, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion